Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Benign Hematology

Expert Opinion / Commentary · December 02, 2019

2019 Top Stories in Benign Hematology: Chemotherapy-Induced Thrombocytopenia

Written by
Michael H. Kroll MD

 

 Save  Recommend
 Share

Additional Info

  1. Duke WW. The relation of blood platelets to hemorrhagic disease: description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA. 1910;55(14):1185-1192.
  2. Wu Y, Aravind S, Ranganathan G, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Therapeutics. 2009;31 Pt 2:2416-2432.
  3. Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019;19(1):151.
  4. Freireich EJ, Kliman A, Gaydos LA, Schroeder LR. Response to repeated platelet transfusions from the same donor. Ann Intern Med. 1963;59:277-287.
  5. Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(3):283-299.
  6. Guan L, Tian X, Gombar S. Big data modeling to predict platelet usage and minimize wastage in a tertiary care system. Proc Natl Acad Sci U S A. 2017;114(43):11368-11373.
  7. Levy JH, Neal MD, Herman JH. Bacterial contamination of platelets for transfusion: strategies for prevention. Crit Care. 2018;22(1):271.
  8. Slichter SJ, Davis K, Enright H, et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-4114.
  9. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100(10):3457-3469.
  10. Soff GA, Miao Y, Bendheim G, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol. 2019;37(31):2892-2898.

Disclosure statements are available on the authors' profiles:

Michael Kroll MD

Further Reading

Recently Updated